The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." https://ezekielsxfq742921.blogprodesign.com/61437589/elite-investor-pharma-risky-wager